Stock 2105 LAEKNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Laekna, Inc.

Equities

2105

KYG5340S1093

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:39 28/05/2024 BST 		5-day change 1st Jan Change
7.04 HKD +0.14% Intraday chart for Laekna, Inc. -9.16% -64.62%
05-23 US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8% MT
05-23 Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer CI

Valuation

Fiscal Period: December 2023
Capitalization 1 7,056
Enterprise Value (EV) 1 6,333
P/E ratio -10.8 x
Yield -
Capitalization / Revenue 15,012 x
EV / Revenue 13,475 x
EV / EBITDA -20.7 x
EV / FCF -38,101,518 x
FCF Yield -0%
Price to Book 8.02 x
Nbr of stocks (in thousands) 390,100
Reference price 2 18.09
Announcement Date 26/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023
Net sales 1 0.111 0.28 0.47
EBITDA 1 -222.4 -391 -306.2
EBIT 1 -225 -393.3 -308
Operating Margin -202,729.73% -140,470% -65,524.89%
Earnings before Tax (EBT) 1 -749 -781.6 -368.8
Net income 1 -749 -781.6 -368.8
Net margin -674,742.34% -279,140.71% -78,471.06%
EPS 2 -10.54 -10.19 -1.680
Free Cash Flow - -180 -166.2
FCF margin - -64,280.94% -35,366.33%
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 15/06/23 15/06/23 26/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023
Net Debt 1 - - -
Net Cash position 1 269 295 723
Leverage (Debt/EBITDA) - - -
Free Cash Flow - -180 -166
ROE (net income / shareholders' equity) - 51.8% 67%
ROA (Net income/ Total Assets) - -52.4% -27.3%
Assets 1 - 1,492 1,353
Book Value Per Share 2 -15.60 -24.00 2.250
Cash Flow per Share 2 4.170 4.070 1.240
Capex 1 7.32 2.98 0.86
Capex / Sales 6,591.89% 1,065.36% 183.83%
Announcement Date 15/06/23 15/06/23 26/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LAEKNA, INC. Stock Laekna, Inc.
-64.62% 351M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.81% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.09% 106B
BIONTECH SE Stock BioNTech SE
-11.88% 23.4B
ARGENX SE Stock argenx SE
-1.69% 22.1B
GENMAB A/S Stock Genmab A/S
-10.23% 18.34B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.92% 16.59B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.67% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.18% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+14.88% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2105 Stock
  4. Financials Laekna, Inc.